Devices, systems and methods for treating benign prostatic hyperplasia and other conditions

Information

  • Patent Grant
  • 10912637
  • Patent Number
    10,912,637
  • Date Filed
    Thursday, June 6, 2019
    5 years ago
  • Date Issued
    Tuesday, February 9, 2021
    3 years ago
Abstract
Extra-urethral implants and methods of use are disclosed. Implants can treat disorders or diseases of the prostate by, for example, enlarging the lumen of the prostatic urethra.
Description
BACKGROUND

The present invention relates generally to medical devices and methods and more particularly to devices, systems and methods for treating conditions wherein a tissue (e.g., the prostate gland) has a) become enlarged and/or b) undergone a change in form, position, structure, rigidity or force exertion with respect to another anatomical structure and/or c) has begun to impinge upon or compress an adjacent anatomical structure (e.g., the urethra).


Benign Prostatic Hyperplasia (BPH) is one of the most common medical conditions that affect men, especially elderly men. It has been reported that, in the United States more than half of all men have histopathologic evidence of BPH by age 60 and, by age 85, approximately 9 out of 10 men suffer from the condition. Moreover, the incidence and prevalence of BPH are expected to increase as the average age of the population in developed countries increases.


Despite extensive efforts in both the medical device and pharmaco-therapeutic fields, current treatments remain only partially effective and are burdened with significant side effects. Certain devices used to displace urethral tissue, such as urethral stents, can become encrusted due to exposure to urine. This encrustation is an undesirable and problematic side effect.


Thus, there remains a need for the development of new devices, systems and methods for treating BPH as well as other conditions in which one tissue or anatomical structure impinges upon or compresses another tissue or anatomical structure.


SUMMARY

Certain embodiments related to a system for enlarging a lumen of a prostatic urethra. The system includes a delivery tool and an implant carried by the delivery tool. The implant is shaped to at least partially circumscribe the prostatic urethra of a patient. The system also includes a depth guide. The depth guide and delivery tool cooperate to deploy the implant within the peri-urethral space and thereby enlarge the lumen of the prostatic urethra.


In some embodiments, the delivery tool has a sharp surface configured to penetrate the urethral wall. In some embodiments, delivery tool delivers energy to prostatic tissue. In some embodiments, the implant has a sharp surface configured to penetrate the urethral wall. In some embodiments, the implant is carried externally to at least part of the delivery tool. In some embodiments, the implant is carried internally to at least part of the delivery tool. In some embodiments, the system includes a pusher coupled to the implant. In some embodiments, the system includes a locking mechanism coupled to at least one of the delivery tool, the implant, or the pusher. In some embodiments, the implant includes a first section and a second section, and the first section is comparatively more flexible than the second section. In some embodiments, the implant is self expanding. In some embodiments, the delivery tool and the implant each have a radius of curvature and the delivery tool radius of curvature is greater than the implant radius of curvature. In some embodiments, the implant includes a first section and a second section, and the first section is frictionally-engaged with the second section. In some embodiments, the implant is configured to be deployed by overcoming the frictional engagement.





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A and 1B illustrate views of an embodiment in which a depth guide facilitates the delivery of an implant.



FIG. 2 illustrates views of an embodiment in which transmitters and receivers help determine the position of an implant.



FIG. 3 illustrates the use of an embodiment in which the implant transmits light that helps determine its location within tissue.



FIGS. 4A through 4E illustrate views of the challenges of implanting a device that straightens a naturally bent urethra.



FIG. 5 illustrates a view of a delivery tool and implant in which the implant rides on the outside of the delivery tool according to an embodiment. The delivery tool is stiff and sharp as compared to the implant.



FIG. 6 illustrates a view of a delivery tool and implant in which the implant is contained within the delivery tool according to an embodiment. The delivery tool is stiff and sharp as compared to the implant.



FIGS. 7A through 7C illustrate views of a method for placing an implant that is contained within a delivery tool according to an embodiment. A pusher and locking mechanisms facilitate delivery of the implant.



FIGS. 8A through 8C illustrate views of an embodiment of an implant with longitudinal flexibility to accommodate urethral anatomy.



FIG. 9 depicts an embodiment in which the impingement of further hyperplasia on the urethral lumen is limited.



FIGS. 10A through 10C illustrate views of an embodiment in which an implant is placed that provides radial force without significant longitudinal displacement.



FIGS. 11A through 11C illustrate views of an embodiment in which the implant expands after being placed by a delivery tool. The implant is carried within the delivery tool.



FIGS. 12A through 12B illustrate views of an implant that is frictionally connected to itself and deployed using a dilating member according to an embodiment.



FIG. 13 illustrates views of an embodiment in which the delivery tool has a tighter radius than the implant.



FIGS. 14A through 14C illustrative views of an embodiment in which the urethral lumen is enlarged prior to delivery of the implant.



FIGS. 15A through 15C illustrate views of an embodiment in which the implant is placed using an expanding delivery member that is expanded within the bladder.



FIG. 16 illustrates a view of a supra pubic implant delivery method according to an embodiment.



FIGS. 17A through 17C illustrative views of an arcuate implant and its delivery method according to an embodiment.



FIG. 18 illustrates a view of a self-cutting ring-type implant according to an embodiment.



FIG. 19 illustrates a view of a triangular implant according to an embodiment.



FIG. 20 illustrates a view of an implant consisting of nested rings according to an embodiment.



FIG. 21 illustrates a view of a series of implants connected by a flexible spine according to an embodiment.





DETAILED DESCRIPTION

The following description of the preferred embodiments of the invention is not intended to limit the invention to these preferred embodiments, but rather to enable any person skilled in the art to make and use this invention. Disclosed herein are systems and methods for treating conditions wherein a tissue (e.g., the prostate gland) has a) become enlarged and/or b) undergone a change in form, position, structure, rigidity or force exertion with respect to another anatomical structure and/or c) has begun to impinge upon or compress an adjacent anatomical structure (e.g., the urethra).


Mechanically displacing prostatic tissue so as to enlarge the lumen of the prostatic urethra is an attractive long-term solution to BPH. However, as described above, chronic exposure of an implant to urine is undesirable. According to embodiments described herein, implants placed near the urethral boundary of the prostate can provide the mechanical forces necessary to enlarge the lumen of the prostatic urethra while avoiding chronic exposure to urine.


For the purposes of this application, the area of the prostate gland near the urethral surface can be referred to as the extra-urethral portion of the prostate. The extra-urethral portion of the prostate is also that portion of the prostate near enough to the urethral boundary such that the prostatic tissue is comparatively less spongy than the central part of the gland. The extra-urethral portion has sufficient mechanical integrity to hold an implant substantially in place. Because the size, shape, and tissue properties of the prostate can vary significantly from one subject to another, this application defines the extra-urethral region in terms of an approximate position relative to the prostatic urethra and in terms of the mechanical properties of the region. The extra-urethral region may also include, or be referred to as, the urethral wall without being limited exclusively to the membrane layer of the prostate immediately adjacent the prostatic urethra. The extra-urethral region may also include, or be referred to as, the peri-urethral region or peri-urethral tissue. Of course, in this application peri-urethral tissue still refers to the region of the urethra within the prostate.


Certain embodiments described herein place implants in the prostate by puncturing, cutting, dissecting, or otherwise penetrating the extra-urethral region of the prostate. In doing so, it is important to avoid puncturing the anatomy in undesirable locations, such as the urethral sphincter, the bladder, and ejaculation ducts. In certain embodiments, more than one extra-urethral implant is desirable to avoid puncturing such locations in the anatomy. For example, multiple implants could be placed such that one implant is distal to the ejaculation ducts and another implant is proximal to the ejaculation ducts. In this way, multiple implants can be used to provide the necessary mechanical dilation of and long-term stability in the urethral lumen while not substantially damaging sensitive parts of the local anatomy.


In certain embodiments, extra-urethral implants include cutting surfaces to facilitate delivery of the implant into tissue. Other surfaces of any delivery device used may be comparatively blunt such that the cutting is focused at a certain surface of the implant.


In certain embodiments, a delivery tool, member, and/or surface is used to cut, penetrate, dissect, separate, or otherwise provide a point of entry and optionally a path through tissue for an implant. In such embodiments, the delivery tool, member, and/or surface can be sharp, pointed, serrated, or otherwise configured to cut tissue. Further, the delivery tool, member, and/or surface can be configured to instead, or in addition, delivery energy (e.g., radio frequency, ultrasound, and/or laser) to tissue to accomplish the penetration.


In certain embodiments, it is preferable to use selective blunt dissection in the peri-urethral tissue plane TP. In such embodiments, the blunt edges of a dissection tool or of the implant produce blunt dissection in the peri-urethral tissue plane TP, separating the urethra U from portions of the prostate P. A penetrating tip may be used to exit the urethra U and set the depth of the penetration such that the appropriate tissue plane in the extra-urethral region can be accessed. FIGS. 1A and 1B depict the blunt tip 110 of an extra-urethral implant 100 and the tip 140 of a depth guide 150 deployed to an adjustable depth alongside the blunt tip 110. The depth guide 150 ensures delivery of the extra-urethral implant 100 beyond the urethral wall UW by creating space between the implant and the urethral wall UW. The depth guide 150 can be withdrawn at any point during the implantation of the extra-urethral implant 100. Preferably, the depth guide 150 is kept in place until the extra-urethral implant 100 has been deployed in the extra-urethral region such that the extra-urethral implant 100 mechanically displaces prostatic tissue away from the urethral lumen. The depth guide 150 can be removably fastened to the extra-urethral implant 100 by various methods. For example, the depth guide 150 can be fastened with one way tabs such that the depth guide 150 remains fixed to the extra-urethral implant 100 when the two members are pushed but can be released from in gauge meant with the extra-urethral implant 100 when the depth guide 150 is pulled proximally and the extra-urethral implant 100 is held in place. Other equivalent methods are within the scope of this disclosure.


In certain embodiments, the extra-urethral implant is delivered such that it is “wound up” like a spring prior to delivery. Upon removal of the depth guide 150, the implant 100 is configured to unwind and expand its diameter.


In certain embodiments, it is preferable to know the relative locations of the urethral sphincter and bladder with respect to prostate prior to and/or during the implantation of an extra-urethral implant. Further, it may be preferable to know where the extra-urethral implant is being deployed relative to the structures. In such embodiments, the delivery device 200 can include a transurethral imaging device. Typically, imaging devices onboard a delivery device 200 can have transmitters 210 and receivers 210 near the delivery port 220, as depicted in FIG. 2. Other embodiments can provide similar location information using optics systems. For example, in certain embodiments in which the extra-urethral implant is polymeric, the polymeric material can be chosen such that it is capable of transmitting light in addition to having desirable mechanical properties. FIG. 3 depicts the distal end 190 of the implant functions as a beacon, and can be detected by optical sensors 295 on board the delivery device. In one example, the multiple sensors 295 can track the position of the distal end 190 of the implant even though the implant is within the extra-urethral region by detecting the light emitted from the distal end 190 of the implant. By moving the distal end 290 of the delivery device, which allows multiple sensors 295 to collect light, the precise position of the implant can be determined. This kind of precise tracking and positioning can help avoid damaging sensitive parts of the local anatomy.



FIGS. 4A through 4E illustrate the challenges of providing a mechanically-resilient implant in the prostatic urethra. FIG. 4A depicts a view of a bend in the urethra 2. Because the implant is driven into and/or through tissue, the implant should have a sufficient degree of stiffness and strength. FIG. 4B depicts implant 100 within the extra-urethral region after having been driven through tissue. FIG. 4B depicts the urethra 2 as now straightened as compared to its previously bent condition depicted in FIG. 4A. However, over time the mechanical resilience, strength, and stiffness of the implant can have unwanted effects, as depicted in FIG. 4C. The implant in FIG. 4C has caused distortions in the prostatic tissue that in turn later caused migration of the implant 100 through tissue. Further, FIGS. 4D and 4E depict the sharp tip 105 of an implant 100 that migrates or cuts through tissue leading to erosion of tissue 4 and exposure of the implant to urine. As discussed above, chronic exposure to urine can lead to encrustation and further complications.


To accommodate this balance between the strength and stiffness needed to penetrate tissue and the flexibility and conformability needed to avoid damaging tissue in a chronic implant environment, it is preferable in certain embodiments to use a two-stage implantation process. In such a two-stage implantation, a stiff, sharp tool is advanced into tissue. Next a softer and/or less stiff implant is left behind when the delivery tool is retracted. In embodiments in which the first stage of implantation is accomplished by delivering energy to tissue, the implant can remain outside the area where energy is being delivered until implantation. In this way, the implant does not experience the delivery energy, which can be advantageous if the delivery energy would have an adverse effect on the implant.



FIG. 5 illustrates a stiff delivery tool 350 and a comparatively less stiff implant 300 to be left behind when the delivery tool 350 is retracted. The core is stiff and sharp, which is preferable for driving into tissue to enable delivery of the more supple sheath implant 300 around the sharp core. Upon retraction, the comparatively less stiff sheath implant 300 is left behind as the extra-urethral implant. Preferably, the sheath has column strength substantial enough such that it does not peel back from the core when the core is being driven through tissue.



FIG. 6 illustrates another embodiment of a stiff delivery tool 400 and a comparatively less stiff implant 450 to be left behind when to delivery tool 400 is retracted. In this embodiment, the delivery tool 400 is external to the implant 450. The external delivery tool 400 is depicted as having a rectangular cross-section, but other cross-sections that facilitate directed delivery of the extra-urethral implant can also be used. The tip 410 of the delivery tool should be non-coring such that material does not build up at the tip of the delivery tool 400 and retard the progress of the delivery tool 400 and implant 450 through tissue. Advantageously, in this embodiment the implant 450 can have less column strength than the embodiment of FIG. 5 in which the implant is external to the delivery tool because the implant 450 in the embodiment of FIG. 6 is comparatively protected within the delivery tool 400. Further, the implant surface does not pass through tissue during delivery and so the implant 450 sees none of the frictional forces that the implant of the embodiment of FIG. 5 sees since it is external to the delivery tool.



FIGS. 7A through 7C depict the delivery process of embodiments in which both the implant core 450 and the delivery tool 400 are advanced through tissue in the deployment phase. FIG. 7A depicts a helical shape for the distal end 420 of delivery tool 400. Implant core 450 is within this distal end 420 of delivery tool 400. FIG. 7A depicts lock mechanisms 480 at a region proximal to the implant core 450. These lock mechanisms 480 allow the delivery tool 400 and the implant core 450 to be manipulated together or separately by selectively locking or unlocking the delivery tool 400 and the implant core 450 with respect to each other. FIG. 7B depicts delivery school 400 being retracted while the implant pusher 488 is held fixed by some of the locking mechanisms 480. In this way, the internal implant core 450 is extruded into tissue. FIG. 7C further depicts a sectional view to illustrate the implant pusher 488 enabling delivery of the implant 450. The pusher 488 must be long enough to exit the urethra such that the implant 450 is fully embedded away from the urethral lumen, that is, the implant 450 is delivered to an extra-urethral position.



FIGS. 8A through 8C depict embodiments that can accommodate the variations of urethral anatomy while still providing the desired mechanical properties to enlarge the urethral lumen. Extra-urethral implants may need to flex longitudinally to avoid straightening the natural geometry of the urethra. Such straightening could cause discomfort and may lead to migration of the implant within tissue. FIGS. 8A and 8B depict two configurations of an embodiment of a variable strength extra-urethral implant and FIG. 8C depicts the prostatic urethra after implantation of such variable strength extra-urethral implants. As depicted in FIGS. 8A and 8B, an extra-urethral implant can have variable strength segments. Some flexible segments 510 can have hinge-like geometries to relieve longitudinal stress. The extra-urethral implant 500 can act similar to a series of independent rings rather than a straight coil. FIG. 8C depicts wider segments 2′ of the urethra 2 in which the stiffer segments of the extra-urethral implant 500 have enlarged the urethral lumen and narrower segments 2″ in which the flexible segments 510 have exerted less mechanical before action on the urethra 2. Although the entire length of the prostatic urethra has not been enlarged, it is believed that small narrowed segments coupled with a majority of large segments can still reduce or relieve symptoms of BPH.



FIG. 9 depicts a benefit of extra-urethral implants 600 that substantially encircle the urethral lumen 2. The benefit of encircling the urethral lumen is that hyperplasia subsequent to implantation of the extra-urethral implant 600 can be physically prevented from impinging on the urethral lumen. The extra-urethral implant 600 provides a physical barrier from further cell growth that narrows the urethral lumen.


In some embodiments, controlling the extra-urethral implant as it advances longitudinally can be challenging in that it is preferable to keep the implant roughly coaxial with the lumen of the urethra. However, the urethra does not always have a straight geometry. In certain embodiments, the implant can be radially expanding, but without translating significantly along the longitudinal axis of the urethra. FIGS. 10A through 10C depicts an embodiment in which the extra-urethral implant is capable of radial expansion sufficient to displace urethral tissue, but without significant translation along the longitudinal axis of the urethra. FIG. 10A depicts delivery tool 750 within the urethral lumen and extra-urethral implant 700 advancing out of delivery port 780. Extra-urethral implant 700 has a sharp tip which enables it to advance through tissue. Extra-urethral implant 700 is sized and configured such that it provides outwardly radial force to mechanically enlarge the urethral lumen without generating significant longitudinal forces. That is, extra-urethral implant 700 is sized and configured to sufficiently circumscribe, or at least partially circumscribe, the urethral lumen. Multiple extra-urethral implants 700 can be delivered using delivery tool 752 the same prostatic urethra. Delivering multiple extra-urethral implant 700 provides enlargement of the urethral lumen along a length of the prostatic urethra. Such multiple extra-urethral implants 700 also have the benefit of avoiding the straightening problems described above.



FIGS. 11A through 11C illustrate yet another embodiment of an extra-urethral implant 800. In this embodiment, the deployment of the extra-urethral implant 800 can be in two stages. First, deployment tool 850 cuts a deployment path for the implant. Then, the implant 800 is deployed and, within the peri-urethral region, expands to a larger diameter than the deployment tool 850. FIG. 11A depicts a cross-section of the prostatic urethra 2 with entry hole 3. Extra-urethral implant 800 resides in the peri-urethral space. FIG. 11A also depicts a view of the constrained configuration of implant 800 within deployment tool 850. In FIG. 11B, extra-urethral implant 800 is shown advancing relative to the end of the deployment tool 850 and simultaneously expanding to an expanded configuration. As disclosed in other embodiments herein, extra-urethral implant 800 can be advanced relative to deployment tool 850 by various mechanisms, including but not limited to, a pusher. FIG. 11C depicts extra-urethral implant 800 in an expanded and delivered configuration. In this configuration, extra-urethral implant 800 is shown as having overlapping ends but the implant need only circumscribe enough of the prostatic urethra to create the desired mechanical enlargement of the urethral lumen.



FIGS. 12A and 12B depict another embodiment of an extra-urethral implant 900. In this embodiment, the implant is frictionally connected with itself such that after initial deployment, or at a later stage, the implant could be expanded through dilation of urethra and ratcheting of the frictionally connected surfaces. FIGS. 12A and 12B depict a ring having an at least partially external loop that is in interlocking contact with an at least partially internal loop. A dilation member 950, such as a balloon, within the urethra is used to force peri-urethral tissue outward. These outward forces cause the implant to ratchet to a larger diameter. The implant will then hold peri-urethral tissue further way radially from the lumen of the urethra. This implant can be implanted initially using any of the delivery and deployment methods described herein.


One of the challenges of expanding a narrowed urethral lumen with a coil or ring-like device is that the lumen initially has a smaller diameter and tighter radius of curvature than it will have after treatment. Some of the embodiments described herein address that challenge by expanding after deployment. FIG. 13 illustrates an embodiment in which the radius of cutting tool 1050 is tighter than the radius of extra-urethral implant 1000. Cutting tool 1050 is deployed from delivery tool 1080 and cuts into the peri-urethral space to provided deployment path for extra-urethral implant 1000. Cutting tool 1050 sets the initial deployment trajectory of the extra-urethral implant 1000, but after delivery by advancing with respect to the cutting tool 1050 the extra-urethral implant 1000 can assume greater diameter and corresponding lesser radius of curvature.


In yet another embodiment depicted in FIGS. 14A through 14C, a delivery system 1150 can be expanded at the delivery site such that the coil diameter starts deployment at the maximal urethral diameter. That is, rather than using the extra-urethral implant 1100 to expand the urethral diameter, the expansion device 1150 is used to expand the urethral diameter and the extra-urethral implant 1100 is used to maintain such expanded diameter. By expanding the deployment site, the extra-urethral implant 1100 has less diameter change post deployment. Reduced diameter change post deployment can allow for a higher degree of control over the coil trajectory. FIG. 14A shows the delivery system expanded distal to the deployment site and then moved proximally to force the distal end of extra-urethral implant 1100 into the urethral wall before the rest of the implant. By rotating the implant 1100 using members of 1180 while simultaneously pulling delivery system 1150 approximately and/or further expanding delivery system 1150, extra-urethral implant 1100 can be deployed into the peri-urethral space, as depicted in FIGS. 14B and 14C.


In yet another embodiment depicted in FIGS. 15A through 15C, the delivery of the extra-urethral implant 1100 could be from the bladder into the prostatic urethra. In this embodiment, the very large space of the bladder can be used advantageously to position and deliver the extra-urethral implant. The delivery process is similar to that depicted in the embodiment of FIGS. 14A through 14C. In both of these embodiments, a combination of expansion, translation, and direction of rotation works to deliver the extra-urethral implant at the desired location and diameter. Further, access could be suprapubic and into the bladder as depicted in FIG. 16. Such a delivery route can give the operator more control for delivery in the ability to avoid expanding the delivery system in situ.



FIGS. 17A through 17C illustrate an arcuate extra-urethral implant 1200 being positioned in the peri-urethral space to enlarge the urethral lumen. The extra-urethral implant 1200 is carried within deployment tool 1250. As with other embodiments described herein, the deployment tool 1250 cuts into the peri-urethral space and the implant 1200 is advanced with respect to the deployment tool 1250. While within the deployment tool 1250, the extra urethral implant 1200 is in a substantially straight configuration. Upon deployment the extra-urethral implant 1200 can assume an arcuate configuration that helps enlarge the urethral lumen. As with other embodiments described herein, multiple implants can be positioned along the length of the prostatic urethra to achieve the desired level of enlargement.


Recalling the balance between the strength and stiffness needed to penetrate tissue and the flexibility and conformability needed to avoid damaging tissue in a chronic implant environment, other two-stage processes can be used. For example, in some subjects the tissue in the peri-urethral space can be made more mechanically resilient by a denaturing process. That is, the tissue in the peri-urethral space can be exposed to conditions that will “toughen” the tissue. Such conditions include, but are not limited to, exposure to radiofrequency heating, chemical agents, biological agents, laser energy, microwave energy, low temperatures, or equivalent means of altering the mechanical properties of tissue to cross-link portions of the tissue or otherwise stiffen the tissue. In these embodiments, the first stage can include exposure to such conditions prior to, during, or after a cutting/penetration step. Alternatively, the tissue-toughening conditions can be the first stage, and the second stage can be implantation of a self-cutting extra-urethral implant. This two-stage tissue denaturing, toughening, and/or stiffening process can be used with any of the embodiments disclosed herein or their equivalents.


Referring again to the balance between strength and stiffness needed to penetrate tissue and the flexibility and conformability needed to avoid damaging tissue in a chronic implant environment, the surface of an extra-urethral implant can be configured to enhance the mechanical coupling between the peri-urethral tissue and the implant. The peri-urethral space may contain predominantly glandular tissue that has low mechanical resilience. That is, the glandular tissue is significantly less stiff than the implant. This large mismatch in mechanical properties can be reduced by configuring the surface of the extra-urethral implant. Texture or surface features can increase the surface area contact between the implant and the prostatic tissue. Increased contact area increases the strength of the contact between the implant and the prostatic tissue. Thus, this embodiment helps overcome the mechanical mismatch between the soft, spongy prostatic tissue and the extra-urethral implant.



FIG. 18 depicts another embodiment of an extra-urethral implant 1300, which may be implanted by inserting the implant 1300 around a lumen, moving it circumferentially around the lumen using a sharp leading edge 1310 to penetrate tissue.


In the embodiment depicted in FIG. 19 a circumferential implant is modeled after the shape of an obstructed urethra, for instance in a triangular shape, and inserted into extra-urethral tissue. This non-circular shape can address the challenge of displacing prostatic tissue in an anatomically-tolerable way to limit migration and provide long-term implant positional stability.


In the embodiment depicted in FIG. 20, a pair of nested rings, 1510 and 1520, forms the implant 1500. The rings may be introduced in a co-planar configuration and then spread apart to widen a body lumen.


Certain embodiments of the invention include a ring that at least partially circumscribes the urethral lumen. Effective treatment of a length of prostatic urethra may require placement of multiple rings. When multiple rings are placed, one or more of the rings may shift over time and no longer provide effective opening of the urethral lumen. FIG. 21 depicts a series of rings (1600, 1600′) connected by comparatively flexible spine 1650. The spine 1650 can help prevent the rings from shifting, twisting, or otherwise moving out of position. In certain embodiments, the spine 1650 can be attached to the rings 1600, 1600′ after placement of one or more of the rings. In other embodiments, the spine is connected to the rings prior to placement of the rings. FIG. 21 depicts several holes 1610 which aid in connection the spine 1650 to the rings. FIG. 21 also depicts each ring 1600, 1600′ as having slot openings 1630, 1630′, which aid the placement of the rings about the prostatic urethra as described in embodiments disclosed herein. Slot openings 1630 and 1630′ do not have to be rotationally aligned as they are depicted in the FIG. 21 and may preferable be purposely misaligned to prevent a longitudinal segment of the prostatic urethra from being unsupported.


Certain embodiments of the invention include V-shaped extra-urethral implants. The implants are positioned such that the vertex of the V is placed outside the prostatic capsule and the legs of the V penetrate through urethral tissue and terminate in the peri-urethral space. Since the vertex is placed outside the comparatively stiffer prostatic capsule, the vertex is anchored more than it would be if it was placed within the softer tissue of the prostate gland. With the vertex placed and the prostatic capsule acting like a fulcrum, the legs of the V spread to open the angle of the V and enlarge the portion of the prostatic urethra adjacent the legs of the V. The legs can be inelastically deformed when spread by a delivery tool, such as an expanding member. Or, the legs may be compressed together during implantation and then spread when released by a delivery tool.


The examples and illustrations included herein show, by way of illustration and not of limitation, specific embodiments in which the subject matter may be practiced. Other embodiments may be utilized and derived therefrom, such that structural and logical substitutions and changes may be made without departing from the scope of this disclosure. Such embodiments of the inventive subject matter may be referred to herein individually or collectively by the term “invention” merely for convenience and without intending to voluntarily limit the scope of this application to any single invention or inventive concept, if more than one is in fact disclosed. Thus, although specific embodiments have been illustrated and described herein, any arrangement calculated to achieve the same purpose may be substituted for the specific embodiments shown. This disclosure is intended to cover any and all adaptations or variations of various embodiments. Combinations of the above embodiments, and other embodiments not specifically described herein, will be apparent to those of skill in the art.

Claims
  • 1. A system for implantation in a lumen of a urethra, comprising: a delivery device configured to carry and deliver an implant;an implant comprising two rings connected by a single flexible spine oriented in a longitudinal direction of the urethra, each of the rings having a non-circular cross-sectional shape such that the cross-sectional shape substantially conforms to the cross-sectional shape of the urethra; anda pusher mechanism and lock mechanism on the delivery device connecting a distal end portion of the delivery device and a proximal end portion of the implant, wherein the lock mechanism comprises at least two opposing surfaces configured to hold a longitudinally oriented portion of the implant between the surfaces.
  • 2. The system of claim 1 wherein the non-circular cross-sectional shape of each of the rings is a triangular shape.
  • 3. The system of claim 1 wherein the implant is configured to have a first configuration to a second configuration.
  • 4. The system of claim 3 wherein the first configuration is a constrained configuration and the second configuration is an expanded configuration.
  • 5. The system of claim 4 wherein the implant is configured to provide an outward radial force on the urethra in the expanded configuration.
  • 6. The system of claim 3 wherein the implant self-expands from the first configuration to the second configuration.
  • 7. The system of claim 3 wherein the delivery device causes the implant to change from the first configuration to the second configuration.
  • 8. The system of claim 3 wherein the implant is configured to provide an outward radial force on the urethra in the second configuration.
  • 9. The system of claim 1 wherein the implant is configured to provide an outward radial force on the urethra.
  • 10. The implant of claim 1 wherein the non-circular cross-sectional shape of each of the rings is a semi-circular shape.
  • 11. An implant for treating a urethral lumen, comprising two rings connected by a single flexible spine oriented in a longitudinal direction of the urethra, each of the rings having a plurality of legs arranged in triangular shape, wherein the implant has a delivery configuration and a deployed configuration and is connected to a delivery device via a pushing mechanism and an locking mechanism on the delivery device, the locking mechanism comprising at least two opposing surfaces configured to hold a longitudinally oriented portion of the implant between the surfaces.
  • 12. The implant of claim 11 wherein the delivery configuration has a smaller cross-section than the deployed configuration.
  • 13. The implant of claim 11 wherein the implant self-expands from the delivery configuration to the deployed configuration.
  • 14. The implant of claim 11 wherein the implant is expanded from the delivery configuration to the deployed configuration using a delivery tool.
  • 15. The implant of claim 11 wherein the implant is configured to provide an outward radial force on the urethra.
  • 16. The implant of claim 11 wherein the implant is configured to provide an outward radial force on the urethra in the deployed configuration.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 16/234,282, filed Dec. 27, 2018, which is a continuation of U.S. application Ser. No. 13/830,811, filed Mar. 14, 2013, now U.S. Pat. No. 10,195,014, both entitled “Devices, Systems and Methods for Treating Benign Prostatic Hyperplasia and Other Conditions,” and each of which is expressly incorporated herein by reference.

US Referenced Citations (724)
Number Name Date Kind
659422 Shidler Oct 1900 A
780392 Wanamaker et al. Jan 1905 A
789467 West May 1905 A
2360164 Frank Oct 1944 A
2485531 William et al. Oct 1949 A
2579192 Alexander Dec 1951 A
2646298 Leary Jul 1953 A
2697624 Thomas et al. Dec 1954 A
2734299 Masson Feb 1956 A
2825592 Mckenzie Mar 1958 A
3326586 Frost et al. Jun 1967 A
3470834 Bone Oct 1969 A
3521918 Hammond Jul 1970 A
3541591 Hoegerman Nov 1970 A
3664345 Dabbs et al. May 1972 A
3713680 Pagano Jan 1973 A
3716058 Tanner Feb 1973 A
3756638 Stockberger Sep 1973 A
3873140 Bloch Mar 1975 A
3875648 Bone Apr 1975 A
3886933 Mori et al. Jun 1975 A
3931667 Merser et al. Jan 1976 A
3976079 Samuels et al. Aug 1976 A
4006747 Kronenthal et al. Feb 1977 A
4137920 Bonnet Feb 1979 A
4164225 Johnson et al. Aug 1979 A
4210148 Stivala Jul 1980 A
4235238 Ogiu et al. Nov 1980 A
4291698 Fuchs et al. Sep 1981 A
4409974 Freedland Oct 1983 A
4419094 Patel Dec 1983 A
4452236 Utsugi Jun 1984 A
4493323 Albright et al. Jan 1985 A
4513746 Aranyi et al. Apr 1985 A
4621640 Mulhollan et al. Nov 1986 A
4655771 Wallsten Apr 1987 A
4657461 Smith Apr 1987 A
4669473 Richards et al. Jun 1987 A
4705040 Mueller et al. Nov 1987 A
4714281 Peck Dec 1987 A
4738255 Goble et al. Apr 1988 A
4741330 Hayhurst May 1988 A
4744364 Kensey May 1988 A
4750492 Jacobs Jun 1988 A
4762128 Rosenbluth Aug 1988 A
4823794 Pierce Apr 1989 A
4863439 Sanderson Sep 1989 A
4893623 Rosenbluth Jan 1990 A
4899743 Nicholson et al. Feb 1990 A
4926860 Stice et al. May 1990 A
4935028 Drews Jun 1990 A
4946468 Li Aug 1990 A
4955859 Zilber Sep 1990 A
4955913 Robinson Sep 1990 A
4968315 Gattuma Nov 1990 A
4994066 Voss Feb 1991 A
5002550 Li Mar 1991 A
5019032 Robertson May 1991 A
5041129 Hayhurst et al. Aug 1991 A
5046513 Gattuma et al. Sep 1991 A
5053046 Janese Oct 1991 A
5078731 Hayhurst Jan 1992 A
5080660 Buelna Jan 1992 A
5098374 Othel-Jacobsen et al. Mar 1992 A
5100421 Christoudias Mar 1992 A
5123914 Cope Jun 1992 A
5127393 McFarlin et al. Jul 1992 A
5129912 Noda et al. Jul 1992 A
5133713 Huang et al. Jul 1992 A
5159925 Neuwirth et al. Nov 1992 A
5160339 Chen et al. Nov 1992 A
5163960 Bonutti Nov 1992 A
5167614 Tessmann et al. Dec 1992 A
5192303 Gattuma et al. Mar 1993 A
5203787 Noblitt et al. Apr 1993 A
5207672 Roth et al. May 1993 A
5217470 Weston Jun 1993 A
5217486 Rice et al. Jun 1993 A
5234454 Bangs Aug 1993 A
5236445 Hayhurst et al. Aug 1993 A
5237984 Williams et al. Aug 1993 A
5254126 Filipi et al. Oct 1993 A
5258015 Li et al. Nov 1993 A
5267960 Hayman et al. Dec 1993 A
5269802 Garber Dec 1993 A
5269809 Hayhurst et al. Dec 1993 A
5300099 Rudie Apr 1994 A
5306280 Bregen et al. Apr 1994 A
5322501 Mahmud-Durrani Jun 1994 A
5330488 Goldrath Jul 1994 A
5334200 Johnson Aug 1994 A
5336240 Metzler et al. Aug 1994 A
5350399 Erlebacher et al. Sep 1994 A
5354271 Voda Oct 1994 A
5358511 Gattuma et al. Oct 1994 A
5364408 Gordon Nov 1994 A
5366490 Edwards et al. Nov 1994 A
5368599 Hirsch et al. Nov 1994 A
5370646 Reese et al. Dec 1994 A
5370661 Branch Dec 1994 A
5372600 Beyar et al. Dec 1994 A
5380334 Torrie et al. Jan 1995 A
5391182 Chin Feb 1995 A
5403348 Bonutti Apr 1995 A
5405352 Weston Apr 1995 A
5409453 Lundquist et al. Apr 1995 A
5411520 Nash et al. May 1995 A
5417691 Hayhurst May 1995 A
5435805 Edwards et al. Jul 1995 A
5441485 Peters Aug 1995 A
5458612 Chin Oct 1995 A
5464416 Steckel Nov 1995 A
5470308 Edwards et al. Nov 1995 A
5470337 Moss Nov 1995 A
5472446 Torre Dec 1995 A
5480406 Nolan et al. Jan 1996 A
5499994 Tihon et al. Mar 1996 A
5501690 Measamer et al. Mar 1996 A
5507754 Green et al. Apr 1996 A
5522846 Bonutti Jun 1996 A
5531759 Kensey et al. Jul 1996 A
5531763 Mastri et al. Jul 1996 A
5534012 Bonutti Jul 1996 A
5536240 Edwards et al. Jul 1996 A
5540655 Edwards et al. Jul 1996 A
5540701 Sharkey Jul 1996 A
5540704 Gordon et al. Jul 1996 A
5542594 McKean et al. Aug 1996 A
5545171 Sharkey et al. Aug 1996 A
5545178 Kensey et al. Aug 1996 A
5549631 Bonutti Aug 1996 A
5550172 Regula et al. Aug 1996 A
5554162 DeLange Sep 1996 A
5554171 Gattuma et al. Sep 1996 A
5562688 Riza Oct 1996 A
5562689 Green et al. Oct 1996 A
5569305 Bonutti Oct 1996 A
5571104 Li Nov 1996 A
5573540 Yoon Nov 1996 A
5578044 Gordon et al. Nov 1996 A
5591177 Lehrer Jan 1997 A
5591179 Edelstein Jan 1997 A
5593421 Bauer Jan 1997 A
5611515 Benderev et al. Mar 1997 A
5620461 Moer et al. Apr 1997 A
5626614 Hart May 1997 A
5630824 Hart May 1997 A
5643321 McDevitt Jul 1997 A
5647836 Blake et al. Jul 1997 A
5653373 Green et al. Aug 1997 A
5665109 Yoon Sep 1997 A
5667486 Mikulich et al. Sep 1997 A
5667488 Lundquist et al. Sep 1997 A
5667522 Flomenblit et al. Sep 1997 A
5669917 Sauer et al. Sep 1997 A
5672171 Andrus et al. Sep 1997 A
5690649 Li Nov 1997 A
5690677 Schmieding et al. Nov 1997 A
5697950 Fucci et al. Dec 1997 A
5707394 Miller et al. Jan 1998 A
5716368 Torre et al. Feb 1998 A
5718717 Bonutti Feb 1998 A
5725556 Moser et al. Mar 1998 A
5725557 Gattuma et al. Mar 1998 A
5733306 Bonutti Mar 1998 A
5741276 Poloyko et al. Apr 1998 A
5746753 Sullivan et al. May 1998 A
5749846 Edwards et al. May 1998 A
5749889 Bacich et al. May 1998 A
5752963 Allard et al. May 1998 A
5775328 Lowe et al. Jul 1998 A
5782862 Bonutti Jul 1998 A
5782864 Lizardi Jul 1998 A
5791022 Bohman Aug 1998 A
5800445 Ratcliff et al. Sep 1998 A
5807403 Beyar et al. Sep 1998 A
5810848 Hayhurst Sep 1998 A
5810853 Yoon Sep 1998 A
5814072 Bonutti Sep 1998 A
5830179 Mikus et al. Nov 1998 A
5830221 Stein et al. Nov 1998 A
5845645 Bonutti Dec 1998 A
5846254 Schulze et al. Dec 1998 A
5861002 Desai Jan 1999 A
5868762 Cragg et al. Feb 1999 A
5873891 Sohn Feb 1999 A
5879357 Heaton et al. Mar 1999 A
5897574 Bonutti Apr 1999 A
5899911 Carter May 1999 A
5899921 Caspari et al. May 1999 A
5904679 Clayman May 1999 A
5904696 Rosenman May 1999 A
5908428 Scirica et al. Jun 1999 A
5908447 Schroeppel et al. Jun 1999 A
5919198 Graves et al. Jul 1999 A
5919202 Yoon Jul 1999 A
5921982 Lesh et al. Jul 1999 A
5921986 Bonutti Jul 1999 A
5928252 Steadman et al. Jul 1999 A
5931844 Thompson et al. Aug 1999 A
5941439 Kammerer et al. Aug 1999 A
5944739 Zlock et al. Aug 1999 A
5948000 Larsen et al. Sep 1999 A
5948001 Larsen Sep 1999 A
5948002 Bonutti Sep 1999 A
5954057 Li Sep 1999 A
5954747 Clark Sep 1999 A
5964732 Willard Oct 1999 A
5971447 Steck Oct 1999 A
5971967 Willard Oct 1999 A
6010514 Burney et al. Jan 2000 A
6011525 Piole Jan 2000 A
6015428 Pagedas Jan 2000 A
6024751 Lovato et al. Feb 2000 A
6030393 Corlew Feb 2000 A
6033413 Mikus et al. Mar 2000 A
6033430 Bonutti Mar 2000 A
6036701 Rosenman Mar 2000 A
6048351 Gordon et al. Apr 2000 A
6053908 Crainich et al. Apr 2000 A
6053935 Brenneman et al. Apr 2000 A
6056722 Jayaraman May 2000 A
6056772 Bonutti May 2000 A
6066160 Colvin et al. May 2000 A
6068648 Cole et al. May 2000 A
6080167 Lyell Jun 2000 A
6086608 Ek et al. Jul 2000 A
6110183 Cope Aug 2000 A
6117133 Zappala Sep 2000 A
6117160 Bonutti Sep 2000 A
6117161 Li et al. Sep 2000 A
6120539 Eldridge et al. Sep 2000 A
6132438 Fleischman et al. Oct 2000 A
6139555 Hart et al. Oct 2000 A
RE36974 Bonutti Nov 2000 E
6143006 Chan Nov 2000 A
6152935 Kammerer et al. Nov 2000 A
6156044 Kammerer et al. Dec 2000 A
6156049 Lovato et al. Dec 2000 A
6159207 Yoon Dec 2000 A
6159234 Bonutti et al. Dec 2000 A
6193714 McGaffigan et al. Feb 2001 B1
6200329 Fung et al. Mar 2001 B1
6203565 Bonutti et al. Mar 2001 B1
6206895 Levinson Mar 2001 B1
6206907 Marino et al. Mar 2001 B1
6228096 Marchand May 2001 B1
6235024 Tu May 2001 B1
6258124 Darois et al. Jul 2001 B1
6261302 Voegele et al. Jul 2001 B1
6261320 Tam et al. Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6280460 Bolduc et al. Aug 2001 B1
6287317 Makower et al. Sep 2001 B1
6290711 Caspari et al. Sep 2001 B1
6306158 Bartlett Oct 2001 B1
6312448 Bonutti Nov 2001 B1
6319263 Levinson Nov 2001 B1
6322112 Duncan Nov 2001 B1
6332889 Sancoff et al. Dec 2001 B1
6382214 Raz et al. May 2002 B1
6387041 Harari et al. May 2002 B1
6398795 McAlister et al. Jun 2002 B1
6398796 Levinson Jun 2002 B2
6425900 Knodel et al. Jul 2002 B1
6425919 Lambrecht Jul 2002 B1
6428538 Blewett et al. Aug 2002 B1
6428562 Bonutti Aug 2002 B2
6436107 Wang et al. Aug 2002 B1
6461355 Svejkovsky et al. Oct 2002 B2
6482235 Lambrecht et al. Nov 2002 B1
6488691 Carroll et al. Dec 2002 B1
6491672 Slepian et al. Dec 2002 B2
6491707 Makower et al. Dec 2002 B2
6494888 Laufer et al. Dec 2002 B1
6500184 Chan et al. Dec 2002 B1
6500195 Bonutti Dec 2002 B2
6506190 Walshe Jan 2003 B1
6506196 Laufer Jan 2003 B1
6514247 McGaffigan et al. Feb 2003 B1
6517569 Mikus et al. Feb 2003 B2
6527702 Whalen et al. Mar 2003 B2
6527794 McDevitt et al. Mar 2003 B1
6530932 Swayze et al. Mar 2003 B1
6533796 Sauer et al. Mar 2003 B1
6544230 Flaherty et al. Apr 2003 B1
6547725 Paolitto et al. Apr 2003 B1
6551328 Kortenbach Apr 2003 B2
6551333 Kuhns et al. Apr 2003 B2
6565578 Peifer et al. May 2003 B1
6569187 Bonutti et al. May 2003 B1
6572626 Knodel et al. Jun 2003 B1
6572635 Bonutti Jun 2003 B1
6572653 Simonson Jun 2003 B1
6582453 Tran et al. Jun 2003 B1
6592609 Bonutti Jul 2003 B1
6595911 LoVuolo Jul 2003 B2
6596013 Yang et al. Jul 2003 B2
6599311 Biggs et al. Jul 2003 B1
6626913 McKinnon et al. Sep 2003 B1
6626916 Yeung et al. Sep 2003 B1
6626919 Swanstrom Sep 2003 B1
6629534 Goar et al. Oct 2003 B1
6638275 McGaffigan et al. Oct 2003 B1
6641524 Kovac Nov 2003 B2
6641592 Sauer et al. Nov 2003 B1
6656182 Hayhurst Dec 2003 B1
6660008 Foerster et al. Dec 2003 B1
6660023 McDevitt et al. Dec 2003 B2
6663589 Halevy Dec 2003 B1
6663633 Pierson Dec 2003 B1
6663639 Laufer et al. Dec 2003 B1
6699263 Cope Mar 2004 B2
6702846 Mikus et al. Mar 2004 B2
6706047 Trout et al. Mar 2004 B2
6709493 DeGuiseppi et al. Mar 2004 B2
6715804 Beers Apr 2004 B2
6719709 Whalen et al. Apr 2004 B2
6730112 Levinson May 2004 B2
6736823 Darois et al. May 2004 B2
6736854 Vadurro et al. May 2004 B2
6740098 Abrams et al. May 2004 B2
6767037 Wenstrom Jul 2004 B2
6770076 Foerster Aug 2004 B2
6773438 Knodel et al. Aug 2004 B1
6773441 Laufer et al. Aug 2004 B1
6790213 Cherok et al. Sep 2004 B2
6790223 Reever Sep 2004 B2
6802838 Loeb et al. Oct 2004 B2
6802846 Hauschild et al. Oct 2004 B2
6821282 Perry et al. Nov 2004 B2
6821285 Laufer et al. Nov 2004 B2
6821291 Bolea et al. Nov 2004 B2
6835200 Laufer et al. Dec 2004 B2
6905475 Hauschild et al. Jun 2005 B2
6908473 Skiba et al. Jun 2005 B2
6921361 Suzuki et al. Jul 2005 B2
6926732 Derus et al. Aug 2005 B2
6951565 Keane et al. Oct 2005 B2
6986775 Morales et al. Jan 2006 B2
6986784 Weiser et al. Jan 2006 B1
6988983 Connors et al. Jan 2006 B2
6991596 Whalen et al. Jan 2006 B2
6991647 Jadhav Jan 2006 B2
6997940 Bonutti Feb 2006 B2
7001327 Whalen et al. Feb 2006 B2
7004965 Gross Feb 2006 B2
7008381 Janssens Mar 2006 B2
7011688 Gryska et al. Mar 2006 B2
7015253 Escandon et al. Mar 2006 B2
7041111 Chu May 2006 B2
7048698 Whalen et al. May 2006 B2
7048747 Arcia et al. May 2006 B2
7060077 Gordon et al. Jun 2006 B2
7063715 Onuki et al. Jun 2006 B2
7065325 Zegelin et al. Jun 2006 B2
7081126 McDevitt et al. Jul 2006 B2
7083638 Foerster Aug 2006 B2
7087073 Bonutti Aug 2006 B2
7089064 Manker et al. Aug 2006 B2
7090690 Foerster et al. Aug 2006 B2
7093601 Manker et al. Aug 2006 B2
7096301 Beaudoin et al. Aug 2006 B2
7104949 Anderson et al. Sep 2006 B2
7105004 DiCesare et al. Sep 2006 B2
7108655 Whalen et al. Sep 2006 B2
7112226 Gellman Sep 2006 B2
7141038 Whalen et al. Nov 2006 B2
7153314 Laufer et al. Dec 2006 B2
7179225 Shluzas et al. Feb 2007 B2
7226558 Nieman et al. Jun 2007 B2
7232448 Battles et al. Jun 2007 B2
7255675 Gertner et al. Aug 2007 B2
7261709 Swoyer et al. Aug 2007 B2
7261710 Elmouelhi et al. Aug 2007 B2
7282020 Kaplan Oct 2007 B2
7288063 Petros et al. Oct 2007 B2
7303108 Shelton Dec 2007 B2
7320701 Haut et al. Jan 2008 B2
7322974 Swoyer et al. Jan 2008 B2
7326221 Sakamoto et al. Feb 2008 B2
7334822 Hines Feb 2008 B1
7335197 Sage et al. Feb 2008 B2
7340300 Christopherson et al. Mar 2008 B2
7399304 Gambale et al. Jul 2008 B2
7402166 Feigl Jul 2008 B2
7416554 Lam et al. Aug 2008 B2
7417175 Oda et al. Aug 2008 B2
7437194 Skwarek et al. Oct 2008 B2
7463934 Tronnes et al. Dec 2008 B2
7470228 Connors et al. Dec 2008 B2
7481771 Fonseca et al. Jan 2009 B2
7485124 Kuhns et al. Feb 2009 B2
7553317 William et al. Jun 2009 B2
7608108 Bhatnagar et al. Oct 2009 B2
7632297 Gross Dec 2009 B2
7645286 Catanese et al. Jan 2010 B2
7658311 Boudreaux Feb 2010 B2
7666197 Orban Feb 2010 B2
7674275 Martin et al. Mar 2010 B2
7682374 Foerster et al. Mar 2010 B2
7695494 Foerster Apr 2010 B2
7704261 Sakamoto et al. Apr 2010 B2
7727248 Smith et al. Jun 2010 B2
7731725 Gadberry et al. Jun 2010 B2
7736374 Vaughan et al. Jun 2010 B2
7758594 Lamson et al. Jul 2010 B2
7766923 Catanese et al. Aug 2010 B2
7766939 Yeung et al. Aug 2010 B2
7780682 Catanese et al. Aug 2010 B2
7815655 Catanese et al. Oct 2010 B2
7850712 Conlon et al. Dec 2010 B2
7862584 Lyons et al. Jan 2011 B2
7887551 Bojarski et al. Feb 2011 B2
7896891 Catanese et al. Mar 2011 B2
7905889 Catanese et al. Mar 2011 B2
7905904 Stone et al. Mar 2011 B2
7909836 McLean et al. Mar 2011 B2
7914542 Lamson et al. Mar 2011 B2
7922645 Kaplan Apr 2011 B2
7951158 Catanese et al. May 2011 B2
8007503 Catanese et al. Aug 2011 B2
8043309 Catanese et al. Oct 2011 B2
8114070 Rubinsky et al. Feb 2012 B2
8145321 Gross Mar 2012 B2
8152804 Elmouelhi et al. Apr 2012 B2
8157815 Catanese et al. Apr 2012 B2
8162960 Manzo Apr 2012 B2
8167830 Noriega May 2012 B2
8211118 Catanese et al. Jul 2012 B2
8216254 McLean et al. Jul 2012 B2
8236011 Harris et al. Aug 2012 B2
8251985 Hoey et al. Aug 2012 B2
8273079 Hoey et al. Sep 2012 B2
8298132 Connors et al. Oct 2012 B2
8303604 Stone et al. Nov 2012 B2
8308765 Saadat et al. Nov 2012 B2
8333776 Cheng et al. Dec 2012 B2
8343187 Lamson et al. Jan 2013 B2
8361112 Kempton et al. Jan 2013 B2
8372065 Hoey et al. Feb 2013 B2
8388611 Shadduck et al. Mar 2013 B2
8388653 Nobis et al. Mar 2013 B2
8394110 Catanese et al. Mar 2013 B2
8394113 Wei et al. Mar 2013 B2
8419723 Shadduck et al. Apr 2013 B2
8425535 McLean et al. Apr 2013 B2
8444657 Saadat et al. May 2013 B2
8454655 Yeung et al. Jun 2013 B2
8465551 Wijay et al. Jun 2013 B1
8480686 Bakos et al. Jul 2013 B2
8491606 Tong et al. Jul 2013 B2
8496684 Crainich et al. Jul 2013 B2
8521257 Whitcomb et al. Aug 2013 B2
8529584 Catanese et al. Sep 2013 B2
8529588 Ahlberg et al. Sep 2013 B2
8562646 Gellman et al. Oct 2013 B2
8585692 Shadduck et al. Nov 2013 B2
8603106 Catanese et al. Dec 2013 B2
8603123 Todd Dec 2013 B2
8603187 Kilemnick et al. Dec 2013 B2
8628542 Merrick et al. Jan 2014 B2
8663243 Lamson et al. Mar 2014 B2
8668705 Johnston et al. Mar 2014 B2
8683895 Nash Apr 2014 B2
8715239 Lamson et al. May 2014 B2
8715298 Catanese et al. May 2014 B2
8734469 Pribanic et al. May 2014 B2
8790356 Darois et al. Jul 2014 B2
8801702 Hoey et al. Aug 2014 B2
8808363 Perry et al. Aug 2014 B2
8814856 Elmouelhi et al. Aug 2014 B2
8828035 Kim Sep 2014 B2
8834458 Neuberger et al. Sep 2014 B2
8880195 Azure Nov 2014 B2
8900293 Forbes et al. Dec 2014 B2
8920437 Harris et al. Dec 2014 B2
8926494 Cook et al. Jan 2015 B1
8945114 Elmouelhi et al. Feb 2015 B2
9034001 Cheng et al. May 2015 B2
9039740 Wales et al. May 2015 B2
9089320 Spivey et al. Jul 2015 B2
9150817 Furihata et al. Oct 2015 B2
9179991 Gozzi et al. Nov 2015 B2
9204922 Hooven Dec 2015 B2
9211155 Fruland et al. Dec 2015 B2
9220874 Pillai et al. Dec 2015 B2
9272140 Gerber Mar 2016 B2
9277914 Wales et al. Mar 2016 B2
9345507 Hoey et al. May 2016 B2
9345867 Browning May 2016 B2
9393007 Darois et al. Jul 2016 B2
9439643 Darois et al. Sep 2016 B2
9459751 Weaver et al. Oct 2016 B2
9526555 Hoey et al. Dec 2016 B2
9549739 Catanese et al. Jan 2017 B2
9561025 Stone et al. Feb 2017 B2
9592044 Weir et al. Mar 2017 B2
9597145 Nelson et al. Mar 2017 B2
9668803 Bhushan et al. Jun 2017 B2
9675373 Todd Jun 2017 B2
9750492 Ziniti et al. Sep 2017 B2
20010041916 Bonutti Nov 2001 A1
20010044639 Levinson Nov 2001 A1
20020049453 Nobles et al. Apr 2002 A1
20020095064 Beyar Jul 2002 A1
20020095154 Atkinson et al. Jul 2002 A1
20020107540 Whalen et al. Aug 2002 A1
20020128684 Foerster Sep 2002 A1
20020161382 Neisz et al. Oct 2002 A1
20020177866 Weikel et al. Nov 2002 A1
20020183740 Edwards et al. Dec 2002 A1
20020193809 Meade et al. Dec 2002 A1
20030023248 Parodi Jan 2003 A1
20030040803 Rioux et al. Feb 2003 A1
20030060819 McGovern et al. Mar 2003 A1
20030078601 Shikhman et al. Apr 2003 A1
20030109769 Lowery et al. Jun 2003 A1
20030120309 Colleran et al. Jun 2003 A1
20030130575 Desai Jul 2003 A1
20030144570 Hunter et al. Jul 2003 A1
20030176883 Sauer et al. Sep 2003 A1
20030191497 Cope Oct 2003 A1
20030199860 Loeb et al. Oct 2003 A1
20030204195 Keane et al. Oct 2003 A1
20030236535 Onuki et al. Dec 2003 A1
20040010301 Kindlein et al. Jan 2004 A1
20040030217 Yeung et al. Feb 2004 A1
20040043052 Hunter et al. Mar 2004 A1
20040044350 Martin et al. Mar 2004 A1
20040078046 Barzell et al. Apr 2004 A1
20040122456 Saadat et al. Jun 2004 A1
20040122474 Gellman et al. Jun 2004 A1
20040143343 Grocela Jul 2004 A1
20040147958 Lam et al. Jul 2004 A1
20040162568 Saadat et al. Aug 2004 A1
20040167635 Yachia et al. Aug 2004 A1
20040172046 Hlavka et al. Sep 2004 A1
20040193191 Starksen et al. Sep 2004 A1
20040193194 Laufer et al. Sep 2004 A1
20040193196 Appling et al. Sep 2004 A1
20040194790 Laufer et al. Oct 2004 A1
20040215181 Christopherson et al. Oct 2004 A1
20040230316 Cioanta et al. Nov 2004 A1
20040243178 Haut et al. Dec 2004 A1
20040243179 Foerster Dec 2004 A1
20040243180 Donnelly et al. Dec 2004 A1
20040243227 Starksen et al. Dec 2004 A1
20040260345 Foerster Dec 2004 A1
20050010203 Edwards et al. Jan 2005 A1
20050033403 Ward et al. Feb 2005 A1
20050055087 Starksen Mar 2005 A1
20050059929 Bolmsjo et al. Mar 2005 A1
20050065550 Starksen et al. Mar 2005 A1
20050101982 Ravenscroft et al. May 2005 A1
20050107811 Starksen et al. May 2005 A1
20050107812 Starksen et al. May 2005 A1
20050137716 Gross Jun 2005 A1
20050154401 Weldon et al. Jul 2005 A1
20050165272 Okada et al. Jul 2005 A1
20050171522 Christopherson Aug 2005 A1
20050177181 Kagan et al. Aug 2005 A1
20050203344 Orban et al. Sep 2005 A1
20050203550 Laufer et al. Sep 2005 A1
20050216040 Gertner et al. Sep 2005 A1
20050216078 Starksen et al. Sep 2005 A1
20050222557 Baxter et al. Oct 2005 A1
20050251157 Saadat et al. Nov 2005 A1
20050251159 Ewers et al. Nov 2005 A1
20050251177 Saadat et al. Nov 2005 A1
20050251206 Maahs et al. Nov 2005 A1
20050267405 Shah Dec 2005 A1
20050273138 To et al. Dec 2005 A1
20050283189 Rosenblatt Dec 2005 A1
20050288694 Solomon Dec 2005 A1
20060004410 Nobis et al. Jan 2006 A1
20060020276 Saadat et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060025750 Starksen et al. Feb 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025789 Laufer et al. Feb 2006 A1
20060025819 Nobis et al. Feb 2006 A1
20060026750 Ballance Feb 2006 A1
20060030884 Yeung et al. Feb 2006 A1
20060058817 Starksen et al. Mar 2006 A1
20060079880 Sage et al. Apr 2006 A1
20060079881 Christopherson et al. Apr 2006 A1
20060089646 Bonutti Apr 2006 A1
20060095058 Sivan et al. May 2006 A1
20060167477 Arcia et al. Jul 2006 A1
20060178680 Nelson et al. Aug 2006 A1
20060199996 Caraballo et al. Sep 2006 A1
20060241694 Cerundolo Oct 2006 A1
20060265042 Catanese et al. Nov 2006 A1
20060271032 Chin et al. Nov 2006 A1
20060276481 Evrard et al. Dec 2006 A1
20060276871 Lamson et al. Dec 2006 A1
20060282081 Fanton et al. Dec 2006 A1
20070049929 Catanese et al. Mar 2007 A1
20070049970 Belef et al. Mar 2007 A1
20070060931 Hamilton et al. Mar 2007 A1
20070073322 Mikkaichi et al. Mar 2007 A1
20070073342 Stone et al. Mar 2007 A1
20070088362 Bonutti et al. Apr 2007 A1
20070100421 Griffin May 2007 A1
20070112385 Conlon May 2007 A1
20070142846 Catanese et al. Jun 2007 A1
20070173888 Gertner et al. Jul 2007 A1
20070179491 Kratoska et al. Aug 2007 A1
20070179496 Swoyer et al. Aug 2007 A1
20070198038 Cohen et al. Aug 2007 A1
20070260259 Fanton et al. Nov 2007 A1
20080009888 Ewers et al. Jan 2008 A1
20080021445 Elmouelhi et al. Jan 2008 A1
20080021485 Catanese et al. Jan 2008 A1
20080033458 McLean et al. Feb 2008 A1
20080033488 Catanese et al. Feb 2008 A1
20080039833 Catanese et al. Feb 2008 A1
20080039872 Catanese et al. Feb 2008 A1
20080039874 Catanese et al. Feb 2008 A1
20080039875 Catanese et al. Feb 2008 A1
20080039893 McLean et al. Feb 2008 A1
20080039894 Catanese et al. Feb 2008 A1
20080039921 Wallsten et al. Feb 2008 A1
20080045978 Kuhns et al. Feb 2008 A1
20080051810 To et al. Feb 2008 A1
20080058710 Wilk Mar 2008 A1
20080065120 Zannis et al. Mar 2008 A1
20080082113 Bishop et al. Apr 2008 A1
20080086172 Martin et al. Apr 2008 A1
20080091220 Chu Apr 2008 A1
20080091237 Schwartz et al. Apr 2008 A1
20080119874 Merves May 2008 A1
20080154378 Pelo Jun 2008 A1
20080161852 Kaiser et al. Jul 2008 A1
20080195145 Bonutti et al. Aug 2008 A1
20080208220 Shiono et al. Aug 2008 A1
20080228202 Cropper et al. Sep 2008 A1
20080269737 Elmouelhi et al. Oct 2008 A1
20090012537 Green Jan 2009 A1
20090018553 McLean et al. Jan 2009 A1
20090060977 Lamson et al. Mar 2009 A1
20090112234 Crainich et al. Apr 2009 A1
20090112537 Okumura Apr 2009 A1
20090118762 Crainch et al. May 2009 A1
20090177288 Wallsten Jul 2009 A1
20090198227 Prakash Aug 2009 A1
20100010631 Otte et al. Jan 2010 A1
20100023022 Zeiner et al. Jan 2010 A1
20100023024 Zeiner et al. Jan 2010 A1
20100023025 Zeiner et al. Jan 2010 A1
20100023026 Zeiner et al. Jan 2010 A1
20100030262 McLean et al. Feb 2010 A1
20100030263 Cheng et al. Feb 2010 A1
20100049188 Nelson et al. Feb 2010 A1
20100063542 Burg et al. Mar 2010 A1
20100114162 Bojarski et al. May 2010 A1
20100130815 Gross et al. May 2010 A1
20100286106 Gat et al. Nov 2010 A1
20100286679 Hoey et al. Nov 2010 A1
20100298948 Hoey et al. Nov 2010 A1
20100324669 Hlavka et al. Dec 2010 A1
20110040312 Lamson et al. Feb 2011 A1
20110046648 Johnston et al. Feb 2011 A1
20110060349 Cheng et al. Mar 2011 A1
20110077676 Sivan et al. Mar 2011 A1
20110144423 Tong et al. Jun 2011 A1
20110152839 Cima et al. Jun 2011 A1
20110160747 McLean et al. Jun 2011 A1
20110166564 Merrick et al. Jul 2011 A1
20110190758 Lamson et al. Aug 2011 A1
20110196393 Eliachar et al. Aug 2011 A1
20110202052 Gelbart et al. Aug 2011 A1
20110218387 Lamson et al. Sep 2011 A1
20110245828 Baxter et al. Oct 2011 A1
20110276081 Kilemnik Nov 2011 A1
20110276086 Al-Qbandi et al. Nov 2011 A1
20120010645 Feld Jan 2012 A1
20120059387 Schanz et al. Mar 2012 A1
20120165837 Belman et al. Jun 2012 A1
20120203250 Weir et al. Aug 2012 A1
20120245600 McLean et al. Sep 2012 A1
20120265006 Makower et al. Oct 2012 A1
20130096582 Cheng et al. Apr 2013 A1
20130178871 Koogle et al. Jul 2013 A1
20130211431 Wei et al. Aug 2013 A1
20130253574 Catanese et al. Sep 2013 A1
20130253662 Lamson et al. Sep 2013 A1
20130261383 Catanese et al. Oct 2013 A1
20130261665 Yeung et al. Oct 2013 A1
20130267772 Catanese et al. Oct 2013 A1
20130268001 Catanese et al. Oct 2013 A1
20130274799 Catanese et al. Oct 2013 A1
20130289342 Tong et al. Oct 2013 A1
20130296639 Lamson et al. Nov 2013 A1
20130296889 Tong et al. Nov 2013 A1
20130296935 McLean et al. Nov 2013 A1
20130325143 Lamson et al. Dec 2013 A1
20140005473 Catanese et al. Jan 2014 A1
20140005690 Catanese et al. Jan 2014 A1
20140012192 Bar-On Jan 2014 A1
20140088587 Merrick et al. Mar 2014 A1
20140221981 Cima et al. Aug 2014 A1
20140236230 Johnston et al. Aug 2014 A1
20140288637 Clerc et al. Sep 2014 A1
20150112299 Forbes et al. Apr 2015 A1
20150157309 Bird Jun 2015 A1
20150257908 Chao et al. Sep 2015 A1
20150335393 Ciulla et al. Nov 2015 A1
20160000455 Golan et al. Jan 2016 A1
20160038087 Hunter Feb 2016 A1
20160051735 Slepian Feb 2016 A1
20160081736 Hoey et al. Mar 2016 A1
20160089140 Kawaura et al. Mar 2016 A1
20160096009 Feld Apr 2016 A1
20160120647 Rogers et al. May 2016 A1
20160206370 Fruland et al. Jul 2016 A1
20160242894 Davis Aug 2016 A1
20160302904 Ogdahl et al. Oct 2016 A1
20160317180 Kilemnik Nov 2016 A1
20170000598 Bachar Jan 2017 A1
20170128741 Keltner et al. May 2017 A1
20170135830 Harkin et al. May 2017 A1
Foreign Referenced Citations (112)
Number Date Country
2477220 Nov 2007 CA
1697633 Nov 2005 CN
101795641 Aug 2010 CN
102112064 Jun 2014 CN
105919695 Sep 2016 CN
10159470 Jun 2003 DE
0246836 Dec 1991 EP
0464480 Jan 1992 EP
0274846 Feb 1994 EP
0632999 Jan 1995 EP
0667126 Aug 1995 EP
1016377 Jul 2000 EP
1482841 Dec 2004 EP
1082941 Mar 2005 EP
1584295 Oct 2005 EP
1006909 Jan 2007 EP
1852071 Nov 2007 EP
1584295 Feb 2008 EP
1884198 Feb 2008 EP
1884199 Feb 2008 EP
1670361 Apr 2008 EP
1331886 Dec 2008 EP
1482840 Dec 2008 EP
2243507 Oct 2010 EP
1484023 May 2011 EP
2345373 Jul 2011 EP
2345374 Jul 2011 EP
2049023 Dec 2014 EP
3167845 May 2017 EP
2750031 Dec 1997 FR
5836559 Mar 1983 JP
09122134 May 1997 JP
3370300 Jan 2003 JP
2004344427 Dec 2004 JP
2009521278 Jun 2009 JP
2011529745 Dec 2011 JP
2012143622 Aug 2012 JP
20060009698 Feb 2006 KR
2062121 Jun 1996 RU
2112571 Jun 1998 RU
2128012 Mar 1999 RU
2221501 Jan 2004 RU
825094 Apr 1981 SU
1987001270 Mar 1987 WO
1992010142 Jun 1992 WO
1993004727 Mar 1993 WO
1993015664 Aug 1993 WO
1995000818 Jan 1995 WO
2000040159 Jul 2000 WO
2001026588 Apr 2001 WO
2001028432 Apr 2001 WO
2001039671 Jun 2001 WO
2001049195 Jul 2001 WO
2001095818 Dec 2001 WO
2002028289 Apr 2002 WO
2002030335 Apr 2002 WO
2002032321 Apr 2002 WO
2002058577 Aug 2002 WO
2003039334 May 2003 WO
2003077772 Sep 2003 WO
2004000159 Dec 2003 WO
2004017845 Mar 2004 WO
2004019787 Mar 2004 WO
2004019788 Mar 2004 WO
2004030569 Apr 2004 WO
2004066875 Aug 2004 WO
2004080529 Sep 2004 WO
2004103189 Dec 2004 WO
2005034738 Apr 2005 WO
2005065412 Jul 2005 WO
2005094447 Oct 2005 WO
2006127241 Nov 2006 WO
2006127431 Nov 2006 WO
2007048437 May 2007 WO
2007053516 May 2007 WO
2007064906 Jun 2007 WO
2007075981 Jul 2007 WO
2008002340 Jan 2008 WO
2008006084 Jan 2008 WO
2008014191 Jan 2008 WO
2008043044 Apr 2008 WO
2008043917 Apr 2008 WO
2008097942 Aug 2008 WO
2008132735 Nov 2008 WO
2008142677 Nov 2008 WO
2009009617 Jan 2009 WO
2009072131 Jun 2009 WO
2010011832 Jan 2010 WO
2010014821 Feb 2010 WO
2010014825 Feb 2010 WO
2010065214 Jun 2010 WO
2010086849 Aug 2010 WO
2010106543 Sep 2010 WO
2011084712 Jul 2011 WO
2012018446 Feb 2012 WO
2012079548 Jun 2012 WO
2012079549 Jun 2012 WO
2012091952 Jul 2012 WO
2012091954 Jul 2012 WO
2012091955 Jul 2012 WO
2012091956 Jul 2012 WO
2012123950 Sep 2012 WO
2014003987 Jan 2014 WO
2014035506 Mar 2014 WO
2014145381 Sep 2014 WO
2014153219 Sep 2014 WO
2014200764 Dec 2014 WO
2015101975 Jul 2015 WO
2016134166 Aug 2016 WO
2017017499 Feb 2017 WO
2017081326 May 2017 WO
2017112856 Jun 2017 WO
Non-Patent Literature Citations (42)
Entry
Bacharova, O.A., et al. “The Effect of Rhodiolae rosea Extract on Incidence Rate of Superficial Bladder Carcinoma Relapses”, Kozin 1995.
Berges, Richard, et al. “Alternative Minimalinvasive Therapien Beim Benignen Prostatasyndrom”, Medizin, Jg. 104, Heft 37, Sep. 14, 2007.
Borzhievski, et al., “Tactics of the Surgical Treatment of Patients With Prostatic Adenoma and Acute Urinary Retention,” Urologia Nefrol (Mosk), Jan.-Feb. 1987, (1):39-43.
European Search Report for EP Application No. 06770621.8, dated Sep. 20, 2012.
European Search Report for EP Application No. 06845991.6, dated Mar. 22, 2013.
European Search Report for EP Application No. 07840462.1, dated May 29, 2012.
European Search Report for EP Application No. 08729001.1, dated Feb. 4, 2014.
European Search Report for EP Application No. 08772483.7, dated Feb. 12, 2015.
European Search Report for EP Application No. 11154962.2, dated May 19, 2011.
European Search Report for EP Application No. 11154976.2, dated Jun. 6, 2011.
European Search Report for EP Application No. 11814950.9, dated Sep. 8, 2015.
European Search Report for EP Application No. 11852778.7, dated Nov. 19, 2015.
European Search Report for EP Application No. 11854148.1, dated Oct. 20, 2017.
European Search Report for EP Application No. 13810314.8, dated Apr. 6, 2016.
European Search Report for EP Application No. 17150545.6, dated Sep. 11, 2017.
Hartung, Rudolf, et al. “Instrumentelle Therapie der benignen Prostatahyperplasie”, Medizin, Deutsches Arzteblatt 97, Heft 15, Apr. 14, 2000.
Hofner, Klaus, et al., “Operative Therapie des benignen Prostatasyndroms”, Medizin, Dtsch Arztebl, 2007; 104(36):A 2424-9.
Hubmann, R. “Geschichte der transurethralen Prostataeingriffe”, Geschichte der Medizin, Urologe [B], 2000, 40:152-160.
International Search Report for PCT Application No. PCT/US2006/019372, dated May 2, 2008.
International Search Report for PCT Application No. PCT/US2006/048962, dated Dec. 10, 2008.
International Search Report for PCT Application No. PCT/US2007/074019, dated Jul. 25, 2008.
International Search Report for PCT Application No. PCT/US2008/053001, dated Jun. 17, 2008.
International Search Report for PCT Application No. PCT/US2008/069560, dated Sep. 8, 2008.
International Search Report for PCT Application No. PCT/US2009/052271, dated Apr. 7, 2010.
International Search Report for PCT Application No. PCT/US2009/052275, dated Oct. 9, 2009.
International Search Report for PCT Application No. PCT/US2011/041200, dated Feb. 17, 2012.
International Search Report for PCT Application No. PCT/US2011/065348, dated Jun. 21, 2012.
International Search Report for PCT Application No. PCT/US2011/065358, dated Jun. 21, 2012.
International Search Report for PCT Application No. PCT/US2011/065377, dated Aug. 29, 2012.
International Search Report for PCT Application No. PCT/US2011/065386, dated Jun. 28, 2012.
International Search Report for PCT Application No. PCT/US2013/044035, dated Sep. 6, 2013.
Jonas, U., et al., “Benigne Prostatahyperplasie”, Der Urologe 2006—[Sonderheft] 45:134-144.
Kruck, S., et al., “Aktuelle Therapiemoglichkeiten des Benignen Prostata—Syndroms”, J Urol Urogynakol, 2009; 16(1): 19-22.
Miyake, Osamu. “Medical Examination and Treatment for BPH,” Pharma Med, vol. 22, No. 3, 2004, p. 97-103.
Reich, O., et al., “Benignes Prostatasyndrom (BPS),” Der Urologe A Issue vol. 45, No. 6, Jun. 2006, p. 769-782.
Schauer, P., et al. “New applications for endoscopy: the emerging field of endoluminal and transgastric bariatric surgery”, Surgical Endoscopy, (Apr. 24, 2006), 10 pgs.
Sharp, Howard T., M.D., et al. “Instruments and Methods—The 4-S Modification of the Roeder Knot: How to Tie It”, Obstetrics & Gynecology, p. 1004-1006, vol. 90, No. 6, Dec. 1997.
Takashi, Daito. “Low-Invasive Treatment for BPH”, Medico vol. 34, No. 10, p. 366-369, 2000.
Teruhisa, Ohashi. “Urinary Dysfunction by Lower Urinary Tract Obstraction in Male”, Pharma Medica, vol. 8, No. 8, p. 35-39, 1990.
Tomohiko, Koyanagi, et al., “Surgery View of 21st Century,” Urological Surgery, vol. 84, No. 1, p. 47-53, 2001.
Trapeznikov, et al., “New Technologies in the Treatment of Benign Prostatic Hyperplasia”, Urologia Nefrol (Mosk), Jul.-Aug. 1996, (4):41-47.
Yeung, Jeff. “Treating Urinary Stress Incontenance Without Incision with Endoscopic Suture Anchor & Approximating Device,” Aleeva Medical, Inc., 2007.
Related Publications (1)
Number Date Country
20190365522 A1 Dec 2019 US
Continuations (2)
Number Date Country
Parent 16234282 Dec 2018 US
Child 16433054 US
Parent 13830811 Mar 2013 US
Child 16234282 US